| May 2017 |
#20. #17 AND #18 AND #19 |
37 |
| #19. #13 OR #14 OR #15 OR #16 |
3,004 |
| #19. #13 OR #14 OR #15 OR #16 |
64,034 |
| #17. #1 OR #2 OR #3 OR #4 OR #5 OR #6 |
3,512,600 |
| #16. ‘plr’ |
2,678 |
| #15. ‘platelet-to-lymphocyte ratio’ |
766 |
| #14. ‘platelet to lymphocyte ratio’ |
766 |
| #13. ‘platelet lymphocyte ratio’/exp |
1,245 |
| #12. ‘esophagus carcinoma’ |
15,242 |
| #11. ‘esophageal carcinoma’ |
7,771 |
| #10. ‘esophageal cancer’ |
24,793 |
| #9. ‘esophagus neoplasm’ |
17 |
| #8. ‘esophageal neoplasm’ |
421 |
| #7. ‘esophagus cancer’/exp |
57,252 |
| #6. ‘mortality’ |
1,073,552 |
| #5. ‘survival’ |
1,391,365 |
| #4. ‘outcome’ |
2,054,741 |
| #3. ‘prognostic’ |
359,252 |
| #2. ‘prognoses’ |
9,581 |
| #1. ‘prognosis’/exp |
605,644 |
